All In MedTech

FDA Clearance Tracker · P010047-S036

PROGEL PLEURAL AIR LEAK SEALANT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 13, 2015 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 13, 2015

Approved

Time to decision

217 days

Received Jul 11, 2014. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P010047-S036
Device name
PROGEL PLEURAL AIR LEAK SEALANT
Applicant
Neomend, Inc.
Applicant location
Irvine, CA
Received
Jul 11, 2014
Decided
Feb 13, 2015
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010047

Device type

Device class
Class III

Every decision under product code NBE

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE PROGEL PLEURAL AIR LEAK SEALANT (PALS). THE SINGLE USE PROGEL PLEURAL AIR LEAK SEALANT DEVICE IS INDICATED FOR APPLICATION TO VISCERAL PLEURA AFTER STANDARD VISCERAL PLEURAL CLOSURE WITH, FOR EXAMPLE, SUTURES OR STAPLES, OF VISIBLE AIR LEAKS INCURRED DURING RESECTION OF LUNG PARENCHYMA.

Source documents

Other decisions for Neomend, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.